Filing summary
Entity discrepancy: The supplied filing is Helius Medical Technologies, Inc.’s Form 10-Q, not a filing for Solana Co. It covers the quarter and nine months ended September 30, 2018; financial amounts below are in U.S. dollars unless noted.
Business context and reporting period
Helius is a pre-revenue neurotechnology company developing the PoNS, an investigational non-invasive device used with therapy to address neurological conditions. The company reported no product revenue and continued to fund development and commercialization preparations.
Key financial metrics
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Nine months 2017 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $2.3m | $3.8m | $7.8m | $11.1m |
| General and administrative expense | $2.6m | $2.2m | $13.6m | $5.9m |
| Total operating expenses | $4.9m | $6.0m | $21.4m | $17.0m |
| Net loss | $4.5m | $12.9m | $23.5m | $24.3m |
| Basic loss per share | $0.19 | $0.67 | $1.06 | $1.32 |
At September 30, 2018, cash was $12.4m, total current assets $12.7m, and total current liabilities $17.8m. Current liabilities included $14.3m of derivative financial instrument liabilities, primarily warrants; the company reported working capital of $9.2m after excluding those derivative liabilities. Total liabilities were $17.8m, and stockholders’ deficit was $4.5m. No conventional borrowings are identified in the provided balance sheet.
For the first nine months, operating cash use was $14.5m, investing cash use $0.4m, and financing cash provided $21.7m. Cash increased $6.8m from $5.6m at year-end 2017. Financing included $18.4m of gross proceeds from the April offering and $4.6m from option and warrant exercises, partly offset by issuance costs.
Material changes versus prior comparable periods
- Q3 net loss narrowed by $8.4m year over year, mainly because derivative fair-value results improved from a $6.0m loss to a $0.4m gain, and operating expenses fell by $1.1m.
- For the nine months, net loss narrowed by $0.8m, despite operating expenses increasing $4.4m. G&A rose $7.8m, including higher stock-based compensation, while R&D declined $3.3m as the registrational clinical trial and device development work progressed or concluded.
- Cash increased following the April 2018 public offering and exercises of options and warrants. Stock-based compensation expense was $7.2m for the nine months, versus $1.5m a year earlier.
- Effective April 1, 2018, the company changed its functional currency from Canadian dollars to U.S. dollars. This changed the classification of certain options and warrants between equity and liabilities and contributed to foreign-exchange and derivative fair-value effects.
Outlook, commentary, risks, and unusual items
- During Q3, Helius submitted a request to the FDA for de novo classification and 510(k) clearance. The filing says the submission was supported by clinical data from 163 patients in two randomized controlled trials. FDA authorization remained pending at the filing date.
- Health Canada issued a Class II medical device license in October 2018. Helius also reported planned U.S. clinical experience programs, expected to begin patient recruitment in Q4 2018, and anticipated European and Australian marketing authorization applications.
- In November 2018, the Canadian distribution partner had engaged two founding clinics; the company expected clinics to operate in Q4 2018 and patient treatment to begin in Q1 2019. These are forward-looking expectations, not reported results.
- Management stated that the company had never generated product revenue, expected continued operating losses and cash outflows, and required additional funding. The filing says these circumstances raise substantial doubt about the company’s ability to continue as a going concern; additional capital may not be available on acceptable terms.
- Warrants are measured using Level 3 fair-value inputs and accounted for as liabilities. The $3.4m nine-month derivative fair-value loss was non-cash; these valuation changes materially affect reported earnings and liabilities.
- A U.S. Government-related agreement creates material commercialization and intellectual-property risks if PoNS is not authorized or available for purchase by December 31, 2021. A separate $2.0m contractual penalty to A&B may apply in specified circumstances; management assessed payment under the amended provision as remote.
- Helius’s alliance with Heuro includes potential funding of up to CAD$1.0m of operating costs, subject to agreement and a 50% cap, plus a 50/50 sharing of net profit or loss. Heuro was treated as an unconsolidated variable interest entity because Helius concluded it did not direct the activities most affecting its performance.
- The company disclosed foreign-currency exposure and stated it does not hedge that exposure. It reported no material legal proceedings and said disclosure controls were effective.
Most important facts for investors to verify
- Confirm the issuer: this source is Helius Medical Technologies, Inc., not Solana Co.
- Check subsequent FDA decisions, PoNS commercialization progress, and whether Canadian clinics began treating patients as projected.
- Assess cash burn, financing needs, and the going-concern uncertainty against subsequent funding and operating developments.
- Review warrant terms, derivative-liability valuation assumptions, and potential dilution from outstanding options and warrants.
- Track the December 31, 2021 U.S. Government commercialization deadline and related intellectual-property, data, and penalty provisions.